DocGo Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DocGo Inc. on August 16, 2026. The filing primarily announces the entry into a Material Definitive Agreement for the acquisition of Hicuity Health, Inc. ("Hicuity") and references the release of financial results for the quarter ended June 30, 2026.
Key Financial Metrics and Transaction Terms
Merger Consideration:
- Closing Stock Consideration: 2.0% of DocGo's fully diluted common stock outstanding at the effective time.
- Earnout Shares: Up to 3.5% of DocGo's fully diluted common stock, subject to vesting based on market capitalization thresholds and a downward adjustment for closing indebtedness and expenses.
- Liquidation Preference: The entire merger consideration is payable solely to the holder of Hicuity's Series F Convertible Preferred Stock. All other Hicuity equity holders, options, and warrants will receive no consideration and be cancelled.
Debt and Financing:
- Assumed Indebtedness: DocGo's subsidiary, Ambulnz, will assume Hicuity's existing credit agreement with Perceptive Credit Holdings IV, LP on a joint and several basis.
- Financing Commitment: Perceptive Credit Holdings IV, LP committed to up to $50,000,000 in new senior secured term loans (structured as $12.5M, $12.5M, and $25M tranches) in addition to continuing $52,000,000 of outstanding term loans.
Financial Results: The filing references a press release (Exhibit 99.1) and Non-GAAP financial information (Exhibit 99.2) for the quarter ended June 30, 2026, including adjusted gross margin, adjusted EBITDA, and adjusted operating expenses. Specific numerical values for revenue, profit, or cash flow are not provided in the text of this 8-K.
Material Changes and Agreements
Merger Structure: The transaction is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. Hicuity will survive the merger as a wholly owned subsidiary of Ambulnz.
Consulting Services: A Consulting Services Agreement was executed where Ambulnz will manage Hicuity's non-clinical operations and fund operating expenses in exchange for a weekly management fee equal to Hicuity's gross revenue collections less operating expenses. This agreement terminates upon the closing or termination of the Merger Agreement.
Outlook, Risks, and Contingencies
Conditions to Closing: The merger is subject to customary conditions, including the accuracy of representations, compliance with covenants, absence of governmental prohibitions, and the execution of a definitive credit agreement to assume the indebtedness.
Earnout Risks: The 3.5% Earnout Shares are subject to forfeiture if specified market capitalization thresholds are not met by the earnout expiration date. No upward adjustment of consideration is permitted.
Termination Rights: Either party may terminate the agreement in cases of material breach, failure to perform obligations, or a final governmental order prohibiting the transaction.
Insurance: Ambulnz will procure a representations and warranties insurance policy to cover losses from breaches of Hicuity's representations.
Investor Verification Checklist
- Verify the specific market capitalization thresholds required for the 3.5% Earnout Shares to vest.
- Review the full text of the Merger Agreement (Exhibit 2.1) for details on the downward adjustment mechanism for Earnout Shares.
- Examine the Non-GAAP reconciliation (Exhibit 99.2) to understand the adjustments made to GAAP figures for the quarter ended June 30, 2026.
- Confirm the terms of the new $50 million financing commitment and the status of the existing $52 million debt assumption.
- Assess the impact of the "Deemed Liquidation Event" on Hicuity's existing capital structure and the cancellation of non-Series F equity.